Trial
NCT04179864
A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Epizyme, Inc.
Collaborators
—
Condition
Metastatic Prostate Cancer
Intervention
Tazemetostat
Why stopped
The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in metastatic castration resistant prostate cancer and the primary endpoint was not met for this study. There were no safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-10